
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
A 6-year-old with a significant past medical history of asthma is rushed to the emergency department at midnight after experiencing a cyanotic spell.






